wjpmr, 2024, 10(1), 106-112

SJIF Impact Factor: 5.922

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Research Article

ISSN 2455-3301

WJPMR

IMPORTANCE OF CIRCULATING DNA IN CLINICAL DIAGNOSIS

Luis Inglada Galiana*[1], Blanca Martín Armentia[2] and Angel San Miguel Hernández[3]

[1]Internal Medicine Service. Rio Hortega University Hospital. Valladolid. Spain.
[2]Laboratory Technician. Rio Hortega University Hospital. Valladolid. Spain.
[3]Department of Health Sciences International University of La Rioja (UNIR). Spain.

***Corresponding Author: Luis Inglada Galiana**

Internal Medicine Service. Rio Hortega University Hospital. Valladolid. Spain.

Article Received on 09/10/2023 **Article Revised on 29/10/2023** **Article Accepted on 19/11/2023**

ABSTRACT

This review studies the nature, detection, and clinical applications of circulating DNA, emphasizing its revolutionary potential in personalized medicine and early disease diagnosis, especially in oncology. Circulating DNA, consisting of free DNA fragments in the blood plasma, has emerged as a promising biomarker for various medical conditions. The document covers its origin, release mechanisms, and current methodologies for detection and analysis, highlighting both traditional and advanced techniques in terms of sensitivity and specificity. Clinically, circulating DNA is particularly valuable in oncology for early cancer detection, treatment response monitoring, and recurrence detection. It also has applications in non-invasive prenatal diagnosis and the identification of genetic diseases, opening new avenues in preventive and personalized medicine. The document explores its emerging use in cardiovascular and autoimmune diseases. Through case studies and clinical evidence, recent research highlighting both the promising results and limitations of using circulating DNA is summarized. Technical challenges and clinical considerations are discussed, emphasizing the need for greater accuracy and standardization in detection methods. Looking to the future, ongoing innovations and their potential impact on the field are explored, projecting circulating DNA as a fundamental pillar in the evolution of personalized medicine. The conclusion reaffirms the importance of circulating DNA in clinical diagnosis, highlighting its transformative role in early disease detection and medical treatment personalization.

KEYWORDS: Circulating DNA, clinical diagnosis, biomarkers, cancer, genetic diseases, personalized medicine.

INTRODUCTION

Historical Context

The concept of circulating DNA has traveled a fascinating path from its discovery to becoming a crucial diagnostic tool. The history begins in 1948, when Mandel and Metais first identified free nucleic acids in human plasma. However, it wasn't until the 1970s that Leon and colleagues reported the presence of circulating DNA in cancer patients, marking a milestone in understanding its clinical potential. Subsequent research focused on understanding the nature and origin of this extracellular DNA, discovering it originates from various sources, including apoptotic and necrotic cells, as well as from living cells through active processes. The 1990s saw significant technological advancements, especially with the introduction of polymerase chain reaction (PCR), enabling more precise and sensitive detection of circulating DNA.

Clinical Significance

Circulating DNA has emerged as a crucial biomarker in multiple medical fields, manifesting its clinical importance in areas such as oncology for early cancer detection, treatment response monitoring, and identifying specific genetic mutations for targeted therapy. It allows for "liquid biopsy," providing a less invasive alternative to traditional biopsies. In non-invasive prenatal diagnosis, it enables detecting fetal chromosomal abnormalities in maternal blood, reducing the need for invasive procedures like amniocentesis. In cardiovascular and autoimmune diseases, circulating DNA can reflect cell death and inflammation, providing information on disease progression and treatment response. In transplants, donor DNA detection in recipients can serve as an early indicator of graft rejection. In summary, circulating DNA represents a significant advancement in modern medicine, offering a less invasive and more dynamic approach to the diagnosis and monitoring of various diseases.[1-4]

Physiology and Biology of Circulating DNA

Origin and Nature

Circulating DNA (cDNA) refers to DNA fragments found freely in blood plasma or serum. These fragments are predominantly double-stranded and vary in size, typically measuring between 150-200 base pairs, roughly the size of a nucleosome. cDNA can originate from both normal and pathological cells.

Sources of Circulating DNA:

Apoptotic and Necrotic Cells: Apoptosis and necrosis contribute significantly to cDNA. During apoptosis, DNA fragments into nucleosome units, while in necrosis, DNA is released in larger fragments due to cell disintegration.

Tumor Cells: In cancer patients, a proportion of cDNA can derive from tumor cells (circulating tumor DNA). This DNA may contain mutations, chromosomal rearrangements, and other genomic alterations characteristic of the primary tumor.

Fetal Cells: During pregnancy, fetal DNA enters the maternal bloodstream, allowing non-invasive prenatal diagnosis.

Graft Cells in Transplants: In organ transplant recipients, donor DNA can be detected in the recipient's circulation.

Mechanisms of Release

cDNA is released into the bloodstream through various mechanisms:

Apoptosis and Necrosis: Programmed cell death (apoptosis) and accidental cell death (necrosis) are the main pathways for cDNA release. In apoptosis, DNA fragments orderly, while in necrosis, cell lysis leads to the release of larger DNA fragments.

Active Secretion: Some cells can actively release DNA into the extracellular space, mediated by extracellular vesicles like exosomes or direct secretion mechanisms.

Inflammation and Cell Stress: Under stress or inflammation, cells can release DNA as part of the immune response or as a cellular signaling mechanism.

Tissue Damage: Physical or chemical damage to tissues can also result in DNA release into the bloodstream.

Thus, circulating DNA is a dynamic component of blood plasma, whose origin and release mechanisms reflect various physiological and pathological processes in the body. Its study provides valuable information about these processes and opens new avenues for disease diagnosis and monitoring.[5-7]

Detection and Analysis Methods of Circulating DNA

Liquid biopsy involves examining cancer-related material (such as DNA) in a blood sample. While liquid biopsy cannot currently replace tumor biopsy, researchers are studying its benefits and best applications. Liquid biopsies show promise for guiding personalized cancer management and will ultimately help healthcare providers detect certain types of cancer.

Traditional and Advanced Techniques

The advancement in detection and analysis technologies has been crucial for the study of circulating DNA (cDNA). These techniques range from traditional methods to more advanced and high-precision approaches.(fig 1)

Traditional Techniques

Real-Time Quantitative PCR (qPCR): This technique has been widely used to quantify cDNA. It is based on the amplification of specific DNA sequences and allows the detection of mutations and genomic variations. However, its sensitivity is limited by the need to know specific sequences to amplify.

Electrophoresis and Southern Blot: These older methods allow visualization and quantification of cDNA but lack the sensitivity and specificity necessary to detect genetic variations or low levels of cDNA.

Advanced Techniques

Next-Generation Sequencing (NGS): NGS allows massive and parallel sequencing of multiple DNA fragments. This technique has revolutionized cDNA analysis, enabling the identification of mutations, copy number variations, and other genomic changes with high precision.

Digital PCR: Offers greater sensitivity and specificity compared to traditional qPCR. Digital PCR divides the DNA sample into thousands of fractions, allowing individual amplification of DNA fragments, improving the detection of rare genetic variants.

Biosensors and Nanotechnology: The development of biosensors and the use of nanotechnology have enabled ultra-sensitive cDNA detection. These methods can detect

Sensitivity and Specificity

The choice of detection and analysis method largely depends on the required sensitivity and specificity:

Sensitivity: Refers to the ability to detect even minimal amounts of cDNA. Digital PCR and NGS are highly sensitive techniques capable of identifying genetic variants present in a very low fraction of the total cDNA.

Specificity: Involves the ability to accurately distinguish between different DNA sequences. NGS is particularly

effective in this aspect, as it can sequence and analyze multiple genome regions simultaneously.

While traditional techniques like qPCR remain useful for specific applications, advancements in NGS and digital PCR have significantly transformed the field of cDNA analysis, offering unprecedented sensitivity and specificity. These advancements have greatly expanded the possibilities of using cDNA in clinical diagnosis, disease monitoring, and personali.



Figure 1: Source of Circulating DNA.

Applications in Clinical Diagnosis of Circulating DNA

Oncology

Circulating DNA (cDNA) has revolutionized oncology, providing new pathways for early cancer detection, treatment response monitoring, and recurrence detection.

Early Cancer Detection: cDNA can contain tumor-specific mutations, enabling early-stage cancer detection. Identifying specific genetic patterns in cDNA can signal the presence of tumors much before they are clinically detectable.

Treatment Response Monitoring: cDNA analysis allows real-time assessment of oncological treatment efficacy. A decrease in tumor-specific cDNA levels can indicate a positive response to treatment.

Recurrence Detection: The emergence of tumor-specific mutations in cDNA can be an early indicator of recurrence, enabling quicker and personalized interventions.

Genetic and Prenatal Diseases

cDNA has also found important applications in non-invasive prenatal diagnosis and the identification of genetic diseases.

Non-Invasive Prenatal Diagnosis: The presence of fetal DNA in maternal blood allows for the detection of chromosomal and genetic anomalies in the fetus without pregnancy risk, including tests for syndromes like Down, Edwards, and Patau.

Identification of Genetic Diseases: cDNA can be used to identify genetic mutations associated with hereditary diseases, allowing early diagnosis and implementation of management and prevention strategies.

Other Diseases

The use of cDNA extends beyond oncology and genetics, finding applications in a variety of other diseases.

Cardiovascular Diseases: cDNA can indicate tissue damage in cardiovascular diseases. For example, elevated levels of cDNA can be a marker of myocardial infarction.

Autoimmune Diseases: In autoimmune diseases, cDNA analysis can help identify gene expression patterns contributing to disease pathology, facilitating more precise diagnosis and treatment personalization.

Infectious Diseases: cDNA is also being explored as a tool for detecting and monitoring infectious diseases, especially those caused by hard-to-cultivate or detect pathogens by traditional methods.

Hence, circulating DNA has become a valuable tool in clinical diagnosis, offering promising applications across

a wide range of medical fields. Its ability to provide precise and non-invasive genetic information makes it a crucial resource in personalized medicine and improving health outcomes.

Case Studies and Clinical Evidence of Circulating DNA

Recent Research

Circulating DNA (cDNA) has been the subject of numerous clinical studies in recent years, highlighting its potential in various areas of medicine.

Oncology: A recent study demonstrated the efficacy of cDNA in early detection of multiple cancers in asymptomatic individuals, using next-generation sequencing analysis to identify specific tumor mutations in cDNA.

Prenatal Diagnosis: Research has shown the accuracy of cDNA in detecting fetal trisomies, such as Down syndrome, with high precision and no risk to the fetus.

Cardiovascular Diseases: Studies have used cDNA to identify biomarkers of myocardial damage after an infarct, providing valuable information on the extent of damage and response to treatment.[14-20]

RESULTS AND LIMITATIONS

Results

High Sensitivity and Specificity: In oncology, cDNA has shown high sensitivity and specificity in detecting tumor mutations, even at early disease stages.

Non-Invasive Diagnosis: In prenatal diagnosis, cDNA offers a non-invasive alternative to procedures like amniocentesis, reducing the risk of complications.

Real-Time Monitoring: In cardiovascular diseases, cDNA allows real-time monitoring of tissue damage and treatment efficacy.

Limitations

Cost and Accessibility: DNA sequencing technologies can be expensive and are not widely available in all clinical settings.

Data Interpretation: Interpreting cDNA results can be complex, especially in cancer detection, where mutations can be heterogeneous.

False Positives/Negatives: Although sensitivity and specificity are high, there are risks of false positives and negatives, which can lead to misdiagnoses or the need for additional testing.

Limitations in Representativeness: cDNA may not fully reflect the heterogeneity of certain tumors, affecting the accuracy of diagnosis and monitoring.

In conclusion, while circulating DNA offers exciting opportunities in the diagnosis and management of various diseases, it's crucial to be aware of its limitations and challenges. Continuous research and the development of more advanced and accessible technologies are essential to overcome these obstacles and maximize the potential of cDNA in clinical practice.

Challenges and Limitations of Circulating DNA

Technical Aspects

Detection and Analysis

Sensitivity and Specificity: Despite modern techniques being highly sensitive and specific, accurately detecting and quantifying very small amounts of circulating DNA, especially in early disease stages like cancer, remains challenging.

Sample Quality: DNA degradation and contamination can affect sample quality, influencing result accuracy.

Tumor DNA Heterogeneity: In oncology, intratumoral heterogeneity may prevent circulating DNA from fully reflecting the tumor's genetic profile, complicating result interpretation.

Technological Limitations

Despite advancements, certain mutations or genetic alterations can be challenging to detect with current technologies.[21-26]

Clinical Considerations

Interpretation and Application

Interpreting circulating DNA results, particularly in cancer detection, can be complex due to heterogeneous mutations varying among patients.

False Positives/Negatives: Risks of false positives and negatives may lead to misdiagnoses or additional testing.

Clinical Applicability: Integrating circulating DNA results into clinical decision-making can be challenging without clear guidelines or solid evidence.

Cost and Accessibility: The high cost and limited availability of advanced circulating DNA detection technologies can be barriers in clinical practice.

Ethics and Consent: Circulating DNA detection can reveal sensitive genetic information, raising ethical issues and the need for clear informed consent.

Patient Expectations: Interpreting results and communicating with patients can be challenging, especially when results are inconclusive or suggest a poor prognosis.

While circulating DNA offers great potential in diagnosing and managing various diseases, it faces significant technical and clinical challenges. Overcoming these obstacles requires technological advancements,

clear clinical guidelines, and careful consideration of ethical implications and patient communication.[27-29]

Future Prospects and Technological Development of Circulating DNA

Ongoing Innovations

In Terms of Technological Advances

Next-Generation Sequencing (NGS): Continues to evolve, offering increased sensitivity and specificity in detecting circulating DNA, including the ability to identify low-frequency mutations and complex genetic profiles.

Circulating DNA Technologies and Future Perspectives

Cell Capture Technologies: Developing more efficient methods to capture and analyze circulating tumor cells alongside circulating DNA for a comprehensive view of tumor biology.

Data Analysis and Big Data: Enhancements in data analysis and big data integration for more accurate, personalized genetic profile interpretations.

Microfluidics and Nanotechnology: Advances to improve efficiency and reduce costs in circulating DNA testing.

AI Integration: Using artificial intelligence to analyze complex patterns in circulating DNA data, enhancing detection and diagnosis.

POTENTIAL IMPACT

Earlier, More Accurate Diagnosis: Improvements in early disease detection, particularly cancer, leading to more effective treatments and better survival rates.

Real-Time Monitoring: Capability for real-time monitoring of treatment response and therapy adjustments.

Drug Resistance Detection: Early identification of drug resistance, allowing timely treatment regimen changes.

Implications for Personalized Medicine

Targeted Therapies: Using genetic profiles from circulating DNA to develop more targeted, personalized therapies.

Disease Prevention and Management: Potential for disease prevention or more effective management through early detection and personalized intervention.

Predictive Medicine: Predicting susceptibility to certain diseases and responding with personalized preventive strategies.

CHALLENGES AND CONSIDERATIONS

Accessibility and Cost: Ensuring technological advancements are accessible and affordable for a broad range of patients.

Ethics and Privacy: Careful handling of genetic information and consideration of ethical and privacy implications.

Education and Training: Educating and training healthcare professionals in new technologies and personalized medicine approaches.

In conclusion, the field of circulating DNA is on the cusp of significant transformations, driven by technological and analytical advancements. These promise to revolutionize personalized medicine, offering more precise diagnoses, personalized treatments, and a better understanding of disease biology. Addressing challenges related to accessibility, ethics, and education is crucial to maximize the potential of these emerging technologies.

Final Thoughts

Circulating DNA has established itself as a crucial component in clinical diagnosis. Its ability to provide detailed, non-invasive information about various health conditions makes it an invaluable tool in modern medicine. As we move forward, integrating new technologies and analytical approaches promises to further expand its utility, especially in the personalization of medical treatment. However, addressing current challenges in detection, analysis, and clinical applications is essential to ensure that the benefits of circulating DNA are accessible and effectively applied in clinical practice. Continuous education, research, and technological development will be key to fully harnessing the potential of circulating DNA, not just as a diagnostic tool, but also as a pillar in the evolution of personalized and predictive medicine. In summary, circulating DNA represents a dynamic and constantly evolving field with a promising future in clinical diagnosis and health management. Its role in personalized medicine, in particular, is an area of great interest and potential, heralding a new era in patient care and treatment.[30-6]

CONCLUSIONS

Circulating DNA, since its discovery, has emerged as a vital tool in clinical diagnosis, offering a unique window into the physiology and pathology of the human body.

Physiology and Biology: Its origin, nature, and release mechanisms in the bloodstream underscore its complexity and versatility as a biomarker.

Detection and Analysis Methods: The evolution from traditional to advanced techniques has significantly enhanced the sensitivity and specificity of circulating DNA detection.

Clinical Diagnostic Applications: Its use in oncology, genetic and prenatal diseases, and other pathologies highlights its versatility and capacity to influence the clinical management of various diseases.

Case Studies and Clinical Evidence: Recent studies reinforce its utility and reveal both its potential and limitations.

Challenges and Limitations: Technical aspects and clinical considerations present ongoing challenges that need addressing to optimize its use.

Regarding Future Prospects and Technological Development, ongoing innovations and their implications in personalized medicine suggest a promising future for circulating DNA in the clinical realm.

BIBLIOGRAFIA

1. Mandel, P. and Métais, P. Les acides nucléiques du plasma sanguin chez l'Homme. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, 1948; 142: 241-243.
2. Stroun, M., et al. (1989). Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology, 1989; 46(5): 318-22.
3. Leon, S. A., et al. (1977). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., Mar. 1977; 37(3): 646-50.
4. Anker, P., et al. (1999). Circulating nucleic acids in plasma or serum. Clin Chim Acta, Nov. 2001; 313(1-2): 143-6.
5. Schwarzenbach, H., et al. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, Jun. 2011; 11(6): 426-37.
6. Chetan Bettegowda, MD, Mark Sausen, PhD, Rebecca Leary, PhD, Isaac Kinde, BS, Nishant Agrawal, MD, Bjarne Bartlett, BS, Hao Wang, PhD, Brandon Luber, MS, Kenneth Kinzler, PhD, Bert Vogelstein, MD detection of circulating tumor dna in early and late stage human malignancies Neuro-Oncology, July. 2014; 16(3): iii7.
7. Taija M af Hällström, Maija Puhka, Olli Kallioniemi Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse? EMBO Mol Med., 2015; 7: 994-995.
8. Lo, Y. M., et al. Quantitative analysis of fetal DNA in maternal plasma and serum. Am J Hum Genet. Am J., Apr. 1998; 62(4): 768-75.
9. Giacona, Mary Beth; Ruben, George C.; Iczkowski, Kenneth A.*; Roos, Thomas B.; Porter, Donna M.*; Sorenson, George D.*Cell-Free DNA in Human Blood Plasma Length Measurements in Patients with Pancreatic Cancer and Healthy Controls Pancreas, July, 1998; 17(1): 89-97.
10. Diehl, F., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. Nat Med., Sep. 2008; 14(9): 985-90.
11. Newman, A. M., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. Nat Med., May., 2014; 20(5): 548-54.
12. Dawson, S. J., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. N Engl J Med., Mar. 28, 2013; 368(13): 1199-209.
13. Lo, Y. M., et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med., Dec. 10, 1998; 339(24): 1734-8.
14. Forshew, T., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med., 2012 May 30; 4(136): 136-138. Wan, J. C. M., et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer, Apr., 2017; 17(4): 223-238.
15. De Mattos-Arruda, L., & Caldas, C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol., Mar., 2016; 10(3): 464-74.
16. Heitzer, E., et al. . Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet., Feb., 2019; 20(2): 71-88.
17. Murtaza, M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA., May. 2, 2013; 497(7447): 108-12.
18. Crowley, E., et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol., Aug., 2013; 10(8): 472-84.
19. K., & Alix-Panabières, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol., Jul., 2019; 16(7): 409-424.
20. Robbert J P Rijnders 1, Godelieve C M L Christiaens, Bernadette Bossers, Jasper J van der Smagt, C Ellen van der Schoot, Masja de Haas Clinical applications of cell-free fetal DNA from maternal plasma Obstet Gynecol., Jan, 2004; 103(1): 157-64.
21. Siravegna, G., et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol, Sep. 2017; 14(9): 531-548.
22. Heidary, M., et al. (2014). The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. Breast, Aug. 9, 2014; 16(4): 421.
23. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications Sarah Croessmann 1, Ben Ho Park Clin Adv Hematol Oncol, Mar., 2021; 19(3): 155-161.
24. Garcia-Murillas, I., et al. . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. Sci Transl Med., Aug. 26, 2015; 7(302): 302ra133.
25. De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci., Mar., 2019; 40(3): 172-186. doi: 10.1016/j.tips.2019.01.006. Epub 2019 Feb 5. PMID: 30736982.

26. Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol., Dec. 2014; 25(12): 2304-2313. doi: 10.1093/annonc/mdu480. Epub 2014 Oct 21. PMID: 25336116.
27. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res., Feb. 15, 2001; 61(4): 1659-65. PMID: 11245480
28. Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol, Sep. 1, 2017; 28(9): 2149-2159. doi: 10.1093/annonc/mdx330. PMID: 28911069.
29. Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol, Sep. 1, 2017; 28(9): 2149-2159. doi: 10.1093/annonc/mdx330. PMID: 28911069.30-Volik, S., et al. (2016). Circulating DNA: free, cell-free or tumor-derived? Transl Cancer Res.
30. Kong L, Birkeland AC. Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges. Cancers (Basel), Apr. 14, 2021; 13(8): 1874. doi: 10.3390/cancers13081874. PMID: 33919778; PMCID: PMC8070729.
31. Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, Perlow H, Baker MJ. Liquid biopsies: the future of cancer early detection. J Transl Med., Feb. 11, 2023; 21(1): 118. doi: 10.1186/s12967-023-03960-8. PMID: 36774504; PMCID: PMC9922467.
32. Soelter TM, Whitlock JH, Williams AS, Hardigan AA, Lasseigne BN. Nucleic acid liquid biopsies in Alzheimer's disease: current state, challenges, and opportunities. Heliyon, Apr. 13, 2022; 8(4): e09239. doi: 10.1016/j.heliyon.2022.e09239. PMID: 35469332; PMCID: PMC9034064.
33. Ramalingam N, Jeffrey SS. Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis. Cancer J., Mar/Apr. 2018; 24(2): 104-108. doi: 10.1097/PPO.0000000000000308. PMID: 29601337; PMCID: PMC5880298.
34. Peng Y, Mei W, Ma K, Zeng C. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front Oncol, Nov. 18, 2021; 11: 763790. doi: 10.3389/fonc.2021.763790. PMID: 34868984; PMCID: PMC8637327.
35. Liu S, Wang J. Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy. Curr Issues Mol Biol., Jun. 10, 2022; 44(6): 2695-2709. doi: 10.3390/cimb44060184. PMID: 35735625; PMCID: PMC9222159.
36. Braig ZV. Personalized medicine: From diagnostic to adaptive. Biomed J., Feb. 2022; 45(1): 132-142. doi: 10.1016/j.bj.2019.05.004. Epub 2019 Jul 9. PMID: 35590431; PMCID: PMC9133264.